CA
SRPT icon

Capitolis Advisors’s Sarepta Therapeutics SRPT Stock Holding History

Capitolis Advisors’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-11,796
Closed -$1.06M – 442
2021
Q4 		$1.06M Buy
+11,796
New +$1.01M 0.01% 477

Other funds holding SRPT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capitolis Advisors's SRPT Position: Q1 2022 in Review

Capitolis Advisors sold out of Sarepta Therapeutics (SRPT) in Q1 2022, closing a stake of 11,796 shares — an estimated $1.06M sold.

Capitolis Advisors first reported a position in SRPT in Q4 2021 and held it in 1 quarter. The position peaked at $1.06M in Q4 2021. 328 funds tracked by Wall St. Rank hold SRPT as of Q1 2022.

  • Capitolis Advisors reported no remaining Sarepta Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Capitolis Advisors sold 11,796 Sarepta Therapeutics shares in Q1 2022, an estimated $1.06M.
  • Capitolis Advisors first reported a position in Sarepta Therapeutics in Q4 2021 and held it in 1 quarter.
  • Capitolis Advisors's Sarepta Therapeutics position peaked at $1.06M in Q4 2021.
  • 328 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2022.

Based on Capitolis Advisors's 13F filing for Q1 2022, filed 12 May 2022.